Skip to content
10-Q

Quarterly Report

Maravai LifeSciences Holdings, Inc. MRVI

0001823239-25-000063

← back to feed
Filed
May 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Long Term Debt Q1 2025 · Mar 31, 2025 $289.5M
Long Term Debt Q1 2025 · Dec 31, 2024 $290.49M
Short Term Debt Q1 2025 · Mar 31, 2025 $5.44M
Short Term Debt Q1 2025 · Dec 31, 2024 $5.44M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $285.05M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $322.4M
Stockholders Equity Q1 2025 · Mar 31, 2025 $300.61M
Stockholders Equity Q1 2025 · Dec 31, 2024 $325.29M
Current Liabilities Q1 2025 · Mar 31, 2025 $63.16M
Current Liabilities Q1 2025 · Dec 31, 2024 $56.97M
Total Liabilities Q1 2025 · Mar 31, 2025 $429.48M
Total Liabilities Q1 2025 · Dec 31, 2024 $431.04M
Current Assets Q1 2025 · Mar 31, 2025 $376.28M
Current Assets Q1 2025 · Dec 31, 2024 $429.15M
Total Assets Q1 2025 · Mar 31, 2025 $959.75M
Total Assets Q1 2025 · Dec 31, 2024 $1.01B
Shares Diluted Q1 2025 · Mar 31, 2024 132.33M sh
Capex Q1 2025 · Mar 31, 2024 $5.67M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$8.47M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.09
Eps Basic Q1 2025 · Mar 31, 2024 −$0.09
Sga Expense Q1 2025 · Mar 31, 2024 $40.89M
Rd Expense Q1 2025 · Mar 31, 2024 $5.03M
Net Income Q1 2025 · Mar 31, 2024 −$12.08M
Operating Income Q1 2025 · Mar 31, 2024 −$18.86M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $38.34M
Revenue Q1 2025 · Mar 31, 2024 $64.18M